Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Ultragenyx Pharmaceutical Inc. has received a consensus recommendation of "Moderate Buy" from twelve brokerages, with eleven analysts rating it as a buy.
• The stock showed a 0.5% increase recently and is currently trading at approximately $29.52, significantly below its 52-week high of $60.37.
• In its last quarterly earnings report, Ultragenyx beat analysts' expectations with a revenue of $166.50 million, up 13.2% year-over-year, despite reporting a negative EPS of ($1.17).

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the twelve ratings firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $81.50.

A number of brokerages have weighed in on RARE. Morgan Stanley dropped their price target on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating for the company in a research report on Monday, July 14th. Wells Fargo & Company dropped their price target on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating for the company in a research report on Thursday, July 10th. Guggenheim reissued a "buy" rating and issued a $64.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 20th. Cantor Fitzgerald dropped their price objective on shares of Ultragenyx Pharmaceutical from $112.00 to $105.00 and set an "overweight" rating for the company in a report on Wednesday, August 6th. Finally, Canaccord Genuity Group dropped their price objective on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating for the company in a report on Friday, August 8th.

Ultragenyx Pharmaceutical Trading Down 1.7%

Ultragenyx Pharmaceutical stock traded down $0.51 during midday trading on Friday, hitting $29.27. 1,060,212 shares of the stock were exchanged, compared to its average volume of 1,296,839. Ultragenyx Pharmaceutical has a fifty-two week low of $25.81 and a fifty-two week high of $60.37. The stock has a market capitalization of $2.82 billion, a price-to-earnings ratio of -5.29 and a beta of 0.25. The stock's 50-day simple moving average is $31.69 and its 200 day simple moving average is $35.65.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, beating analysts' consensus estimates of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The business had revenue of $166.50 million during the quarter, compared to analysts' expectations of $161.37 million. During the same period last year, the business earned ($1.52) earnings per share. The business's revenue for the quarter was up 13.2% on a year-over-year basis. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. Equities analysts anticipate that Ultragenyx Pharmaceutical will post -5.18 EPS for the current fiscal year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $37.39, for a total value of $89,922.95. Following the completion of the transaction, the director owned 15,344 shares in the company, valued at approximately $573,712.16. The trade was a 13.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 5.50% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in RARE. California State Teachers Retirement System lifted its holdings in Ultragenyx Pharmaceutical by 0.3% in the 4th quarter. California State Teachers Retirement System now owns 78,051 shares of the biopharmaceutical company's stock valued at $3,284,000 after purchasing an additional 268 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Ultragenyx Pharmaceutical by 76.2% in the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 323 shares in the last quarter. Xponance Inc. lifted its holdings in shares of Ultragenyx Pharmaceutical by 2.8% during the 1st quarter. Xponance Inc. now owns 12,552 shares of the biopharmaceutical company's stock worth $455,000 after acquiring an additional 347 shares during the period. BOKF NA lifted its holdings in shares of Ultragenyx Pharmaceutical by 5.0% during the 4th quarter. BOKF NA now owns 7,976 shares of the biopharmaceutical company's stock worth $336,000 after acquiring an additional 382 shares during the period. Finally, Oak Ridge Investments LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 2.3% during the 1st quarter. Oak Ridge Investments LLC now owns 17,757 shares of the biopharmaceutical company's stock worth $643,000 after acquiring an additional 395 shares during the period. Hedge funds and other institutional investors own 97.67% of the company's stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.